Skip to content
Medical Health Aged Care

$30,000 to be won | QV Healthcare Practitioner Student Scholarship Back For 2024

Ego Pharmaceuticals < 1 mins read

Opening on March 4th 2024, the QV Healthcare Practitioner Student Scholarship will award a total of $30,000 in prize money to undergraduate and postgraduate students in Pharmacy, Medicine or Nursing courses in a bid to further the education of the next generation of Australian healthcare practitioners.

Entrants are asked to complete a short essay related to sensitive skin, an area QV understands well having spent decades specialising in skincare for sensitive and problematic skin. Submissions will be judged by a panel of industry experts including Dr. Fabrizio Spada (Scientific Affairs Manager, Ego Pharmaceuticals), Michelle Privitera (President, Eczema Association of Australasia) and Vivienne Speirs (President, Australian Dermatology Nurses' Association).

QV Skincare, part of the Ego Pharmaceuticals portfolio, has a long and close association with healthcare practitioners since the brand was first founded following a request from the dermatology ward of Melbourne’s iconic Queen Victoria Hospital.

Decades on, the QV brand remains family owned, Australian made, and synonymous with quality and innovation. With over 50 QV products sold in more than 20 nations around the world, QV is proud to be Australia’s #1 recommended sensitive skincare brand by healthcare professionals^, a testament to the trust dermatologists, GPs and pharmacists have in the brand.

The QV Healthcare Practitioner Student Scholarship is open from March 4th until June 27th 2024. Interested parties can enter via www.qvskincare.com.au/scholarship.html

^Fifth Quadrant, Sponsored by Ego Pharmaceuticals, OTC Skincare, n = 374, October 2023.


Contact details:

For all media enquiries, please contact Ego Pharmaceuticals:

Courtney Barlow | courtney.barlow@egopharm.com

Media

More from this category

  • Medical Health Aged Care
  • 15/01/2025
  • 20:54
Glaxo SmithKline

Local scientific discovery Omjarra (momelotinib) TGA approved for Australians with rare bone marrow cancer

MELBOURNE PHOTO-FILMING OPPORTUNITY: THURSDAY 16TH JANUARY 2025 DATE: Thursday 16th January 2025 TIME: 10.30 – 11.30am LOCATION: 3 Torresdale Road, Toorak, Melbourne INTERVIEWEES: Prof…

  • Contains:
  • Medical Health Aged Care
  • 15/01/2025
  • 10:33
Monash University

The Lancet Diabetes & Endocrinology: Global Commission proposes major overhaul of obesity diagnosis, going beyond BMI to define when obesity is a disease.

A global Commission, published in The Lancet Diabetes & Endocrinology and endorsed by 75 medical organisations around the world [1], presents a novel, nuanced approach to diagnose obesity, based on other measures of excess body fat in addition to body mass index (BMI), and objective signs and symptoms of ill health at the individual level. The proposal is designed to address limitations in the traditional definition and diagnosis of obesity that hinder clinical practice and healthcare policies, resulting in individuals with obesity not receiving the care they need. By providing a medically coherent framework for disease diagnosis, the Commission also…

  • Medical Health Aged Care
  • 14/01/2025
  • 17:10
Galderma

Galderma Premieres Positive Interim Results Demonstrating the Efficacy of Its Injectable Aesthetics Portfolio in Addressing Facial Volume Loss as a Result of Medication-driven Weight Loss

Three-month interim data from first-of-its-kind trial demonstrate that the combination of Sculptra® and Restylane® Lyft™ or Contour™ effectively improved the facial aesthetic appearance of…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.